NASDAQ · Health care

Hemab Therapeutics Holdings, Inc. (COAG)

At June 30, 2026 it held $237.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.

Watch COAG in 60 seconds

Price

$40.73

-4.86% on the day · November 10, 2026

52-week range $23.00 to $55.42

Market cap

$1.9B

Key facts about Hemab Therapeutics Holdings, Inc.

Net worth: Hemab Therapeutics Holdings, Inc. has a market value (market cap) of $1.9B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

What Hemab Therapeutics Holdings, Inc. does

Hemab Therapeutics Holdings, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker COAG.

Earnings: every quarter and the next report date

Latest SEC filings

What Hemab Therapeutics Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

November 6, 2026
Passive stake changed SCHEDULE 13G/A
September 24, 2026
Executive or director change8-KHemab Therapeutics elected Keli Walbert to its Board of Directors and Audit Committee.
August 14, 2026
Passive stake (5% or more) SCHEDULE 13G
August 14, 2026
Passive stake (5% or more) SCHEDULE 13G
August 12, 2026
Passive stake (5% or more) SCHEDULE 13G
August 11, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.80 versus -$12.91.
August 11, 2026
Quarterly results 8-K
August 7, 2026
Passive stake (5% or more) SCHEDULE 13G
August 6, 2026
Passive stake (5% or more) SCHEDULE 13G
August 5, 2026
Passive stake (5% or more) SCHEDULE 13G

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 25, 2026. Insider transactions on SEC

Insider trades

What the people running Hemab Therapeutics Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
June 16, 2026	Ra Capital Management, L.P.10% owner	Boughtindirect	61,523	$24.98	$1.5M	Form 4
June 15, 2026	Ra Capital Management, L.P.10% owner	Boughtindirect	6,146	$24.89	$153K	Form 4
May 20, 2026	Ra Capital Management, L.P.10% owner	Boughtindirect	996	$24.94	$24.8K	Form 4
May 19, 2026	Ra Capital Management, L.P.10% owner	Boughtindirect	3,802	$24.97	$94.9K	Form 4
May 12, 2026	Ra Capital Management, L.P.10% owner	Boughtindirect	6,387	$24.90	$159K	Form 4
May 11, 2026	Ra Capital Management, L.P.10% owner	Boughtindirect	14,149	$24.47	$346.2K	Form 4
May 11, 2026	Ra Capital Management, L.P.10% owner	Boughtindirect	25,720	$25.00	$643K	Form 4
May 8, 2026	Ra Capital Management, L.P.10% owner	Boughtindirect	1,483	$24.98	$37K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns COAG

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
RA Capital Management, L.P.13G, passive with 3 related filers	16.6%	7,729,773	May 11, 2026
AI Den-Mab LLC13D, may seek influence with 4 related filers	10.4%	4,876,344	May 11, 2026
Novo Holdings A/S13G, passive	9%	4,180,550	August 14, 2026
Deep Track Capital, LP13G, passive with 3 related filers	8.15%	3,600,996	May 8, 2026
Fmr LLC13G, passive with 1 related filers	7.9%	3,697,837	August 6, 2026
Capital International Investors13G, passive	7.7%	3,603,876	August 12, 2026
Behzad Aghazadeh13G, passive with 2 related filers	7.06%	3,298,236	August 14, 2026
Sofinnova Crossover II SLP13G, passive with 6 related filers	5.4%	2,511,212	August 5, 2026
Raymond Debbane13G, passive with 7 related filers	5.1%	2,366,235	August 7, 2026

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 55 managers reported a position.

Holder	Shares	Value	Change on quarter
RA Capital Management, L.P.	7,808,627	$286.8M	new
Novo Holdings A/S	4,180,550	$153.6M	new
Fmr LLC	3,697,837	$135.8M	new
Capital International Investors	3,603,876	$132.4M	new
Deep Track Capital, LP	3,602,093	$132.3M	new
Siren, L.L.C.	2,086,834	$76.6M	new
Avoro Capital Advisors LLC	1,925,150	$70.7M	new
Bain Capital Life Sciences Investors, LLC	1,650,000	$60.6M	new
Jpmorgan Chase & Co	1,152,420	$42.3M	new
Vanguard Capital Management LLC	780,758	$28.7M	new
Driehaus Capital Management LLC	715,791	$26.3M	new
Rock Springs Capital Management LP	575,432	$21.1M	new
Bellevue Group AG	550,000	$20.2M	new
Citadel Advisors LLC	523,450	$19.2M	new
BlackRock, Inc.	283,833	$10.4M	new
Deerfield Management Company, L.P.	275,000	$10.1M	new
ExodusPoint Capital Management, LP	218,287	$8M	new
Geode Capital Management, LLC	211,798	$7.8M	new
Braidwell LP	160,000	$5.9M	new
Marshall Wace, Llp	154,674	$5.7M	new

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

3 insiders reported holding 10,661,135 shares in total, about $434.2M at the last price.

Holder	Shares	As of
Ra Capital Management, L.P.10% owner	6,444,6376,444,637 held indirectly	June 16, 2026
Novo Holdings A/S10% owner	4,180,550	May 4, 2026
Maraganore JohnDirector	35,948	May 4, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about COAG

What does Hemab Therapeutics Holdings, Inc. do?

Hemab Therapeutics Holdings, Inc. is a company in the Health care sector, listed on NASDAQ as COAG. Its shares trade on NASDAQ under the ticker COAG.

What is Hemab Therapeutics Holdings, Inc.'s net worth?

Hemab Therapeutics Holdings, Inc. has a market value (market cap) of $1.9B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.

When did Hemab Therapeutics Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.

Similar companies

TSHA

Taysha Gene Therapies, Inc.

ADMA

Adma Biologics, Inc.

IMCR

Immunocore Holdings plc

RXRX

Recursion Pharmaceuticals, Inc.

Compare COAG with

Compare COAG with any company

Follow COAG

Get an email when Hemab Therapeutics Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values Hemab Therapeutics Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.